Metal Modified ZIF-8 MOF for Control Drug Release Study

Abstract

This research introduces a novel nanocomposite, Zn0.5Mn0.5Fe2O4@ZIF-8, which has been developed and tested as a promising nanocarrier for delivering the anticancer drug cisplatin in a controlled manner. This composite combines the impressive surface area and pH-sensitive attributes of ZIF-8 with the unique magnetic and catalytic features of Zn0.5Mn0.5Fe2O4 nanoparticles. The method involved the in situ development of ZIF-8 on the surface of Zn0.5Mn0.5Fe2O4, which was treated with CTAB, and this took place in a methanol medium. The analyses of the structure and morphology confirmed that the formation and encapsulation were achieved successfully.We fine-tuned the drug loading experiments with Response Surface Methodology (RSM) using a Central Composite Design (CCD), and we managed to achieve an impressive drug loading efficiency of 74%. We carried out in vitro release tests under three different pH levels (5.4, 7.4, and 8.5) to mimic the conditions found in tumor environments and the human body. The results indicated that the release profile was responsive to pH changes, peaking at around 75% when the pH was neutral (7.4).We explored different models to analyze how the drug is released, and it turns out that the pseudo-second-order model fit the data really well (R² > 0.99). This suggests that the mechanisms of chemisorption and complex formation play a key role in how the drug is released. The improved formulation displayed a steady release pattern, hinting that it could help cut down on how often doses are needed and lessen adverse effects.To sum it up, this research highlights that Zn0.5Mn0.5Fe2O4@ZIF-8 stands out as a potential multifunctional platform for innovative smart drug delivery systems. It offers adjustable loading and release capabilities, magnetic responsiveness, and finely-tuned release kinetics specifically designed for cancer treatment.